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Abstract
Medications to inhibit the actions of tumour necrosis factor alpha have revolutionized the 
treatment of several pro-inflammatory autoimmune conditions. Despite their many benefits, 
several serious side effects exist and adverse reactions do occur from these medications. While 
many of the medications’ potential adverse effects were anticipated and recognized in clinical 
trials prior to drug approval, several more rare adverse reactions were recorded in the literature as 
the popularity, availability and distribution of these medications grew. Of these potential adverse 
reactions, liver injury, although uncommon, has been observed in some patients. As case reports 
accrued over time and ultimately case series developed, the link became better established 
between this family of medicines and various patterns of liver injury. Interestingly, it appears that 
the majority of cases exhibit an autoimmune hepatitis profile both in serological markers of 
autoimmune liver disease and in classic autoimmune features seen on hepatic histopathology. 
Despite the growing evidence of this relationship, the pathogenesis of this reaction remains 
incompletely understood, but it appears to depend on characteristics of the medications and the 
genetic composition of the patients; it is likely more complicated than a simple medication class 
effect. Because of this still incomplete understanding and the infrequency of the occurrence, 
treatments have also been limited, although it is clear that most patients improve with cessation of 
the offending agent and, in certain cases, glucocorticoid use. However, more needs to be done in 
the future to unveil the underlying mechanisms of this adverse reaction.
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1 Introduction
Tumour necrosis factor alpha (TNF-α) was discovered in 1975 as a protein with a molecular 
weight of 26 kDa, produced by lymphocytes and macrophages, which is expressed on the 
plasma membrane [1–3]. There, its extracellular domain can be cleaved by matrix metallo-
proteinases, which result in release of a soluble 17 kDa form (sTNF-α) [4]. Both membrane-
bound TNF-α (mTNF-α) and sTNF-α forms are active in their trimeric forms, and the two 
forms of TNF may have distinct biological activities. TNF-α is part of a large family of 
proteins with diverse inflammatory, proliferative, apoptotic and antitumoral effects [4]. 
Members of the TNF-α superfamily have both beneficial and potentially harmful effects. 
Although TNF-α, for example, has been linked with physiological proliferation and 
differentiation of B cells under steady-state conditions, it also has been linked with a wide 
variety of diseases, including autoimmune disorders [4].
TNF-α can be either pro- or anti-inflammatory, depending on whether it acts on an effector 
(e.g. macro-phage) or a target (e.g. endothelial) cell, releasing ligand or receptors, 
respectively. The activation of TNF-α receptor (TNF-R) is associated with an acute phase 
reaction, fever, apoptosis and anti-tumour activity [4, 5]. TNF-α is not usually detectable in 
the serum of healthy individuals, but elevated serum and tissue levels are found in many 
inflammatory and infectious conditions, and serum levels correlate with the severity of 
infections [3].
Inhibitors of TNF-α were developed in the 1990s, and the first ones, infliximab and 
etanercept, were approved by the US Food and Drug Administration (FDA) in 1998 for the 
treatment of Crohn’s disease and rheumatoid arthritis (RA), respectively [5, 6]. Thereafter, 
adalimumab was approved in 2002 for RA, certolizumab in 2008 for RA, and golimumab in 
2009 for RA, psoriatic arthritis and ankylosing spondylitis [6].
Many patients with the above inflammatory conditions are now taking anti-TNF-α 
medications on an ongoing basis, as these biological response modifiers are widely 
prescribed to modify the body’s response to inflammation. Sales of anti-TNF-α agents in the 
USA alone topped US$10 billion in 2010 [4]. Initially, adverse events (AEs) associated with 
the use of anti-TNF-α molecules focused on autoimmune features and injection site 
reactions, whereas liver injury was not emphasized in the original labels (Table 1). 
However, an FDA postmarketing surveillance programme received more than 130 reports of 
liver injury resulting from either infliximab or etanercept treatment within 5 years [7]. These 
reports have been extended, and the liver injury due to these agents has been better 
characterized in terms of clinical and histological presentation in the more recent literature 
[8]. Currently, all of the TNF-α antagonists have been associated with drug-induced liver 
injury (DILI) [8]. In addition, these agents carry specific warnings about the risk of 
reactivation of chronic hepatitis B and risks of tuberculosis (TB) and other infections [9]. 
TNF-α inhibitors increase susceptibility to new infections or reactivation of concurrent or 
incident infections. Thus, before their use for therapy, screening for TB [with chest 
radiography and an interferon-gamma (IFN-γ) release assay] and certain viral infections 
(such as hepatitis B virus, hepatitis C virus, cytomegalovirus and herpes virus) is 
recommended [10].
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Two cases of successful treatment with etanercept without recurrent DILI, following a prior 
DILI episode attributed to infliximab, have recently been reported, suggesting that cross-
toxicity or a ‘class effect’ is not universal among the different TNF-α antagonists in all 
patients [11, 12]. However, it has been shown that several TNF-α antagonists have a similar 
ability to elicit the development of serological markers of autoimmunity [8]. These 
compounds have also been associated with reactivation of latent TB, hepatitis B, and 
development of lymphoma, autoantibodies and skin reactions [10].
The purpose of this paper is to review the types, typical clinical features, management and 
prognosis of DILI associated with anti-TNF-α medications.
2 Literature Search
A literature search was conducted in PubMed to identify published articles relevant to our 
focus on adverse reactions to anti-TNF-α agents, with a particular concentration on liver 
injury. Articles published from 1988 through June 2015 were included. The search terms 
used were combinations of the following terms: ‘anti-tumour necrosis factor’, ‘drug-induced 
liver injury’, ‘infliximab’, ‘etanercept’, ‘adalimumab’, ‘certolizumab’ and ‘golimumab’. 
Articles were reviewed and selected on the basis of relevance to our subject matter, and the 
selected articles were reviewed. Articles that were deemed relevant were read and 
scrutinized in detail. Articles were not excluded on the basis of the language in which the 
article was printed, and all articles printed in languages other than English were 
appropriately translated. Articles were excluded if it was felt that the information provided 
in the article was insufficient to conclude that the patient had a drug injury from an anti-
TNF-α medication. Similarly, data that emerged from clinical trials were not included, 
because of the relative paucity of early data on liver injury until individual case reports 
started to emerge. Weight was given to larger case series (n >4), but small case series and 
individual case reports were also reviewed and included. The first large literature case 
review was by Ghabril et al. [8], in 2013, which included 28 cases from the literature and six 
cases from the US Drug-Induced Liver Injury Network (DILIN). Since the publication by 
Ghabril et al., our search uncovered 11 additional case reports and five case series that have 
been published and are reviewed here. The combined cases from these additional reports add 
86 new cases that had not yet been reported when the review by Ghabril et al. was written.
3 Reported Adverse Effects: Focus on DILI
While anti-TNF-α medications are generally considered to be well tolerated, several 
significant adverse effects have been described. In the current manufacturers’ prescribing 
information for infliximab, etanercept, adalimumab, certolizumab and golimumab, several 
warnings and adverse reactions are listed, including the risk of serious infection, 
malignancies, reactivation of hepatitis B, demyelinating disease of the central nervous 
system, pancytopenia, worsening heart failure and triggering of autoimmune disease, 
especially a lupus-like syndrome [13–17]. Therefore, many of the most significant adverse 
effects of the medications appear to be a class effect related to the ability of these agents to 
block the effects of TNF-α. As with most medications, after several years of use, other 
postmarketing adverse reactions were reported. Examples of some of these adverse effects 
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associated with various anti-TNF-α medications have included psoriasis, vasculitis, various 
dermatological reactions, sarcoidosis and ocular reactions [18–20]. That being said, these 
adverse reactions are relatively rare and have occurred in small numbers of subjects, usually 
described in individual case reports. However, there were some postmarketing adverse 
reaction reports of liver injury associated with use of anti-TNF-α medications, which, while 
uncommon, were nonetheless significant [8, 21].
In the initial reports of liver injury associated with infliximab and etanercept that appeared 
in the FDA post-marketing surveillance programme, several other confounding factors or 
potential other sources of liver injury were found. However, it was noted in seven cases that 
there was a strong association with anti-TNF-α medication use [22]. Case reports also 
emerged in the published literature, describing various types of liver injury, including both 
hepatocellular and cholestatic injury patterns associated with anti-TNF-α medications [22–
25]. As the indications for the anti-TNF-α class of medications expanded and usage became 
more widespread, case series were collected, further providing evidence that there was an 
association between TNF-α antagonists and liver injury [26]. Over the past few years, 
several larger studies—including queries of large databases of patients on anti-TNF-α 
therapy and liver injury networks—have been published, and these have helped to better 
characterize the liver injury patterns that are encountered [8, 27–29].
As already mentioned, Ghabril et al. [8] described 34 cases of DILI attributed to anti-TNF-α 
medications. Six of these cases were obtained from the DILIN database, and 28 were 
obtained from literature review. The method of causality assignment used by the US DILIN 
was utilized to assign probability [30, 31]. Roussel-Uclaf Causality Assessment Method 
(RUCAM) scores also were developed. On the basis of the analysis, 34 cases of DILI were 
found in which anti-TNF-α medications were at least the probable cause of the liver injury, 
and they were found to be the likely cause in the majority (21/34) of the cases [8].
Another recent study by Björnsson et al. [27] described 11 cases of liver injury that were 
identified at the National University Hospital of Iceland (Reykjavík, Iceland). Again, the 
RUCAM was used to assign causality, and in the 11 cases described, the anti-TNF-α 
medications were felt to be causative. In the majority (8/11) of the cases, the authors felt it 
was highly probable that the liver injury was due to the anti-TNF-α medications [27]. 
Similarly, a recent paper by Shelton et al. [29] reported a retrospective cohort review of 
patients from two large academic medical centres and their affiliated clinics. These authors 
found 102 cases of elevated serum alanine aminotransferase levels in patients with 
inflammatory bowel disease on anti-TNF-α therapy, of which 48 were felt to be due to anti-
TNF-α therapy, based on RUCAM analysis (Table 2) [29].
When the studies by Ghabril et al. [8], Björnsson et al. [27] and Shelton et al. [29] are 
compared, there are some notable differences, including (inter alia) the definition of liver 
injury and the patient populations studied (Fig. 1a). However, there also are several 
prominent similarities that allow for a better understanding of the nature of the liver injury 
caused by anti-TNF-α medications. First, it appears that the anti-TNF-α medication that 
most commonly causes liver injury is infliximab [8, 27, 29], whereas etanercept and 
adalimumab have been implicated to much lesser degrees (Fig. 1a) [8, 27, 29]. These three 
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anti-TNF-α agents are also the agents that have been prescribed for longer periods and thus 
have been available for a longer duration of use when compared with the newer medications 
in the class. Prescription trends and DILI risks are discussed below.
Second, while there are cholestatic and hepatocellular patterns of liver injury reported in the 
cases described by Ghabril et al. [8], Björnsson et al. [27] and Shelton et al. [29], the 
predominant form seen is a hepatocellular type of liver injury with features of autoimmunity 
[32]. Similarly, in other published cases, there are varying types of liver injury reported, but 
the majority show autoimmune features, such as autoimmune patterns of injury found on 
liver biopsy (many plasma cells, pseudo-rosettes of hepatocytes, etc.) and positive 
serological markers, including high titres of antinuclear antibodies and anti–smooth muscle 
antibodies [23, 25, 33–35].
Furthermore, Rodrigues et al. [36] recently described eight cases of an autoimmune pattern 
of liver injury, many relatively mild in severity, based on biopsy and serological data 
attributed to anti-TNF-α therapy (Table 2).
Interestingly, while all of the anti-TNF-α medications share similar adverse effect profiles, 
and multiple anti-TNF-α agents have been associated with liver injury, it does appear that 
there is more than just a class effect phenomenon at work, because some patients have 
tolerated anti-TNF-α medications without adverse effects after developing a liver injury 
from a different agent in the class [8, 11, 12, 27, 37–39]. Interestingly, there has also been a 
report of a patient developing an autoimmune type of liver injury from infliximab and, after 
recovery, being retreated with infliximab once again without recurrence of the liver injury 
[36]. Until the mechanism of liver injury induced by the anti-TNF-α class of medications is 
fully elucidated, it will be difficult to understand the presence or absence of cross-reactions 
among medications within this class, or even the risk of repeated use of the same agent after 
anti-TNF-α liver injury has occurred in a patient. It remains unclear if anti-TNF agents 
actually precipitate de novo autoimmune hepatitis (AIH), which can relapse without 
precipitants in the absence of immunosuppression. The majority of reported experiences 
indicate a phenotype of DILI with autoimmune features, without relapses even after tapering 
of relatively short-term steroid therapy, when used. In addition, two reported cases of 
infliximab-related DILI with autoimmune features are instructive: in one instance, injury 
due to the drug developed in the postpartum period in a patient who had tolerated infliximab 
since before the pregnancy. This is consistent with an increased risk of development of AIH 
occurring in that period [40]. The persistence of serum aminotransferase abnormalities in 
another patient, which normalized only after a year of steroid therapy, with continued 
immunosuppression thereafter, argue against a self-limited injury and for an 
immunosuppression-responsive AIH [41].
Extra-intestinal manifestations of inflammatory bowel diseases, including primary 
sclerosing cholangitis, are well recognized, and patients with these (and other) disorders 
often are treated with other potentially hepatotoxic agents in addition to anti-TNF-α agents
—for example, methotrexate and sulfasalazine [42]. Thus, assessment of causality of liver 
disease in such patients requires thoroughness and care, such as the detailed Delphic method 
adopted by the US DILIN [30, 31]. As already described, the clinical, laboratory and 
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histopathological features of DILI due to anti-TNF-α agents are usually those of hepatitis 
with autoimmune features, not those of cholestatic-type hepatitis, as occurs in primary 
sclerosing cholangitis. However, in cases of cholestatic-type hepatitis, which can be due to 
anti-TNF-α agents [8], it is important to assess the bile ducts with special care, with 
endoscopic or magnetic retrograde cholangiopancreatography, and perhaps liver biopsy.
The ‘latency’ (the time from the start of an anti-TNF-α drug to development of DILI) is 
variable. Ghabril et al. [8] found within their series of patients that the median time to onset 
of liver injury after starting therapy with an anti-TNF-α medication was 16 weeks (range 2–
52 weeks). Similarly, Björnsson et al. [27] and Shelton et al. [29] described medians of 14 
weeks (range 4–104 weeks) and 18 weeks (range 2–87 weeks), respectively. Shelton et al. 
[29] focused their discussion and data on injury due to infliximab, and DILI due to this agent 
accounted for the vast majority (45/48 cases) of the patients in their series.
Ghabril et al. [8] noted that anti-TNF-α DILI with an autoimmune phenotype (22 cases) was 
associated with a somewhat longer median latency of 16 weeks, compared with 10 weeks in 
cases without autoimmune features (12 cases). These data would suggest that the majority of 
incidents of liver injury that occur secondarily to anti-TNF-α therapy occur within the first 
20 weeks of therapy (Table 2). However, Rodrigues et al. [36] noted a mean onset of liver 
injury after eight doses of anti-TNF-α therapy in their series of eight patients, which would 
be a longer latency of approximately 46 weeks, assuming standard loading and dosing of 
infliximab. Long latencies (up to ~156 weeks) also were recently described by Rösner et al 
[43]. Thus, data from the aforementioned series and published individual case reports 
demonstrate considerable variability in the latency to onset of liver injury after the start of 
anti-TNF-α therapy, ranging from after only one dose to after more than 2 years of therapy 
[8, 27, 43, 44].
As outlined in Table 1, the majority of the cases of intrinsic liver injury associated with anti-
TNF medications were noted in postmarketing reporting. In the current manufacturer 
prescribing information for infliximab, hepatotoxicity is clearly listed in the “Warning and 
Precautions” section as well as in the “Adverse Reactions” section [15]. The prescribing 
information for adalimumab, etanercept, golimumab and certolizumab lists “hepatotoxicity” 
or “elevated liver enzymes” in the “Postmarketing Experience” and/or “Adverse Reactions” 
sections [13–17]. On the basis of this growing body of evidence of anti-TNF induced liver 
injury, it seems appropriate that hepatotoxicity should be prominently listed in the 
manufacturer-supplied prescribing information.
3.1 Prescribing Trends and DILI Risk of Specific Anti-TNF-α Agents
The risk of DILI associated with specific anti-TNF-α agents has been difficult to estimate, 
because of [1] the selective nature of reporting of associated DILI via case reports or case 
series (i.e. an unknown numerator); and [2] the limited data on the number of prescriptions 
(i.e. an unknown denominator). If the risk of DILI were similar for all agents in this class, 
then the overwhelming preponderance of infliximab-related DILI in the literature would 
suggest that infliximab is by far the most prescribed anti-TNF-α agent in this class. However 
a US multi-institutional study indicated that, among 16,022 patients treated with anti-TNF-α 
agents between 1998 and 2007 (for rheumatological, dermatological and inflammatory 
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bowel disease), 4494 were receiving etanercept, 3906 were receiving infliximab and 2084 
were receiving adalimumab [45]. Few data speak to trends in utilization regardless of 
underlying disease. A Stanford University clinical data repository analysis suggested that 
infliximab therapy for inflammatory bowel disease peaked at that centre in 2008, while 
adalimumab use has steadily increased since then [46], and we believe that patterns of use at 
our centres are similar. On the basis of Thomson-Reuters MarketScan® data reporting of 
anti-TNF-α prescriptions for RA, psoriasis, psoriatic arthritis or ankylosing spondylitis 
between 2005 and 2009, the most frequently used agent was etanercept (in 12,065 patients, 
with annual costs of US$15,836 per patient), followed by adalimumab (in 5685 patients, 
with annual costs of US$19,457 per patient), followed by infliximab (in 3902 patients, with 
annual costs of US$24,018 per patient) [47]. A more recent report on non-discounted 
spending on medicine in the USA annually between 2009 and 2013 indicates that the 
greatest increase in expenditure over this period was for adalimumab (a 124 % increase to 
US$5.6 billion), followed by etanercept (a 27 % increase to US$4.7 billion) and infliximab 
(a 28 % increase to US$4.1 billion) [48]. A similar report ranked adalimumab and etanercept 
as first and second among the top ten medicines by expenditure (infliximab was not on the 
list) [49]. Together, these data suggest that infliximab currently is not prescribed more 
commonly than adalimumab or etanercept. Therefore, the more frequent reporting of 
infliximab-related DILI probably reflects a higher risk of DILI with this agent compared 
with others in its class. This is supported by the findings of an Icelandic population-based 
study, which indicated DILI risks of 1 in 120 with infliximab, 1 in 270 with adalimumab and 
1 in 430 with etanercept therapy [27]. A search of the US Adverse Event Reporting System 
(AERS) Spider (http://www.chemoprofiling.org/AERS) was performed. This system 
generates summaries of specific reported AEs with specific drugs [50]. Searches using the 
anti-TNF-α agent names indicated 18,893 reported AEs with infliximab, 45,522 with 
adalimumab, 30,056 with etanercept, 4225 with certolizumab and 779 with golimumab. Of 
these, AIH was reported in 29 instances with infliximab but was not reported with the other 
agents. There were no other reported liver-specific AEs that could represent potential DILI.
3.2 Prevention, Management and Outcomes of DILI Due to Anti-TNF-α Agents
While the causative relationship between the anti-TNF-α family of medications and liver 
injury is becoming clearer, there remain few reliable data to help guide treatment for DILI 
due to these agents. Of greatest importance, of course, is to stop the offending anti-TNF-α 
medication immediately. In some cases, corticosteroids were administered with good results, 
whether used initially or after failure of serum aminotransferase levels to normalize after the 
anti-TNF-α agent was stopped [8, 23–27, 29, 40, 43]. Unfortunately, there is currently not 
an evidence-based treatment strategy that would help clinicians decide which patients would 
benefit most from steroid therapy or guide the duration of therapy. However, in the vast 
majority of the available cases available for review, it appears that the liver injury ultimately 
improves, and while steroid therapy seems to provide some benefit in certain situations, 
whether corticosteroids are truly of benefit or not remains unclear [8, 23–27, 29, 40, 43]. 
There is appropriate concern regarding the use of corticosteroids in patients who are already 
immunosuppressed because of recent administration of anti-TNF-α agents, which are well 
known to increase risks of infections, as already described. Then, too, corticosteroids have 
several other known adverse effects of their own, including weight gain, systemic arterial 
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hypertension, development of hyperglycaemia/diabetes mellitus and alterations of mood. 
However, the risks of such adverse effects may be decreased by use of budesonide rather 
than pred-nis[ol]one, and by limiting the duration of corticosteroid therapy as far as possible.
It has also been recently suggested that concomitant use of disease-modifying anti-rheumatic 
drugs (DMARDs)—typically, anti-inflammatory/immunomodulatory agents—may prevent 
liver injury caused by anti-anti-TNF-α drugs. In a recent retrospective study, Björnsson et 
al. [27] reported that among 33 patients treated with anti-TNF-α agents, those concomitantly 
treated with methotrexate or other DMARDs were less likely to develop DILI.
3.3 Postulated Mechanisms of Pathogenesis of DILI Due to Anti-TNF Agents
Liver enzyme abnormalities can be observed in patients with RA, inflammatory bowel 
disease or psoriasis treated with TNF-α inhibitors. Underlying morbidity, such as viral 
hepatitis or non-alcoholic fatty liver disease, has been implicated in such cases 
contemporaneously with the use of anti-rheumatic and anti-inflammatory drugs with 
established hepatic toxicity [51]. As already described, cases of AIH with concomitant liver 
enzyme abnormalities and circulating antinuclear antibodies [and/or elevated 
immunoglobulin G (IgG) levels] caused by anti-TNF-α have similarly been reported [52]. 
Differentiating AIH from anti-TNF-α-induced DILI is challenging, as both conditions may 
present with similar laboratory and histological features. To date, differential diagnosis has 
been based most firmly on the absence of AIH relapse after the resolution of liver injury 
with or without immunosuppressive therapy and with continuing non-use of the implicated 
anti-TNF-α drug [53]. The great majority of patients with idiopathic AIH will experience 
relapses when systemic corticosteroid therapy or other immunosuppressive therapy is 
discontinued.
TNF-α is a potent inflammatory cytokine, mainly expressed by monocytes/macrophages, T 
cells and natural killer (NK) cells, all of which are either resident or infiltrating hepatic 
leukocytes [54], as well as endothelial cells. TNF-α is initially expressed as its membrane-
bound precursor (mTNF-α) cleaved by the TNF-converting enzyme metalloprotease [also 
known as ADAM 17 endopeptidase; Enzyme Commission (EC) number 3.4.24.86] and 
released in a soluble form (sTNF-α). sTNF-α is biologically active through autocrine and 
paracrine signalling mediated by TNF-R1 and TNF-R2, which are ubiquitously expressed by 
nucleated cells [55]. mTNF-α can act both as a ligand, signalling mainly through TNF-R2 
(and, to a lesser extent, TNF-R1), and as a receptor through reverse signalling in mTNF-α-
expressing/TNF-α-producing cells [56].
Potential mechanisms of the pathogenesis of DILI caused by anti-TNF-α agents vary on the 
basis of the structure, functional properties and biological activities of the aforementioned 
agents (Table 3). As an example of structural differences among anti-TNF-α agents, 
infliximab—the only chimeric mouse–human monoclonal antibody (others are fully human)
—is also the most prone to cause liver injury, as already described. In vitro studies with 
humanized mouse IgG have shown that the three complementarity-determining variable 
regions of both heavy and light segments can elicit CD4+ T cell responses associated with 
numerous human leukocyte antigen (HLA) class II alleles [57]. Although immunogenicity 
of those complementarity-determining regions remains minimal, it is tempting to speculate 
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that this region may be more important in pathogenesis of DILI in subjects with specific 
HLA types, and this helps to account for why DILI occurs in only a few patients treated with 
anti-TNF agents.
From a functional standpoint, binding and neutralizing of sTNF-α is a common feature of 
anti-TNF-α agents, but the several available drugs exert differential effects on mTNF-α. 
Disruption of liver homeostasis by blocking of sTNF-α can promote hepatocyte apoptosis 
and prevent liver regeneration in a transgenic mouse model of chronic hepatitis C infection 
[58]. This adverse reaction to sTNF-α blocking in the liver originates from the ambivalent 
biological activity of the cytokine. For example, sTNF-α promotes caspase 8 activation and 
apoptosis; yet, at the same time, it mitigates cell death by promoting NF-κB activation and 
cell proliferation [59].
Two key differences among anti-TNF-α agents’ biological activities are their opsonizing 
activity and/or ability to trigger reverse signalling. All FDA-approved anti-TNF-α agents 
containing a human IgG fragment crystallizable (Fc) portion (infliximab, etanercept, 
adalimumab and golimumab) can promote antibody-dependent cell-mediated cell death 
(ADCC) of mTNF-α/TNF-α-producing cells (Table 3). The same anti-TNF-α agents 
promote mTNF-α reverse signalling. While not specific only to liver biology, mTNF-α 
reverse signalling has been associated with E-selectin expression, IFN-γ production by T 
cells and alloresponse against endothelial cells [55]. mTNF-α reverse signalling can also 
trigger a pro-inflammatory signal—including, for instance, TNF-α production by 
monocytes/macrophages and NK cytotoxicity (upregulation of perforin, granzyme B 
expression) [56].
While the aforementioned adverse biological effects of anti-TNF-α agents (hepatocyte 
apoptosis, ADCC, pro-inflammatory reverse signalling) have been demonstrated either 
clinically or using experimental models, the direct link between anti-TNF-α agents and liver 
damage remains controversial. Liver damage may indeed be caused by a combination of 
underlying autoimmune diathesis in patients treated with anti-TNF-α agents with potential 
adverse—as well as favourable—biological effects.
4 Conclusion
There is an apparent causative link between anti-TNF-α therapy and liver injury and, while 
the incidence of this AE appears to be relatively low (given the few reports in the literature 
compared with the large number of patients receiving the medications), the liver injury is 
nonetheless significant. In many cases, the liver injury that is sustained appears to have an 
autoimmune pattern, but little is understood about the pathophysiology of this reaction. 
Furthermore, even less is understood regarding the appropriate treatment when this type of 
liver injury does occur. Future studies are needed to further define the mechanism of liver 
injury secondary to anti-TNF-α medications and the optimal role of corticosteroids in this 
patient population after liver injury develops. However, given the relative rarity of such 
reactions, meaningful data to achieve this aim will prove difficult to obtain. Another goal is 
to develop reliable predictors of the risk of DILI due to these agents, so that, in future, the 
development of this adverse effect is avoided.
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Key Points
Drug-induced liver injury (DILI) associated with anti-tumour necrosis factor alpha 
(anti-TNF-α) agents is uncommon but can occur with a wide range of latency 
ranging from a single dose to over 2 years of treatment.
Anti-TNF-α-associated DILI is commonly characterized by autoimmune serological 
and histological features, and responds well to glucocorticoids, with very low rates 
of recurrent autoimmune injury after resolution.
DILI associated with one anti-TNF-α agent has been reported to recur with the use 
of an alternative anti-TNF-α agent after recovery; therefore, close monitoring is 
recommended in these scenarios.
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Fig. 1. 
a Indications for use of anti-tumour necrosis factor alpha (anti-TNF-α) agents among 
subjects who developed drug-induced liver injury (DILI): reported underlying conditions of 
the patients who developed liver injury secondarily to anti-TNF therapy. The numbers of 
subjects in each category are displayed on the chart. CD Crohn’s disease, JIA juvenile 
inflammatory arthritis, Ps psoriasis, PsA psoriatic arthritis, RA rheumatoid arthritis, S 
spondylitis, UC ulcerative colitis. b Anti-TNF-α medications cited in the cases as the cause 
of liver injury, represented as percentages of the total cases presented (note: in the reports by 
Titos-Arcos et al. [39] and Rösner et al. [43], a patient from each report had two separate 
incidents of liver injury due to both adalimumab and etanercept, and both are counted in this 
figure)
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